ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2137

Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis

Lihi Eder1, Laura Coates2, Peter Nash3, Uta Kiltz4, Ennio Lubrano5, Erin McDearmon-Blondell6, Tianming Gao7 and Alexis Ogdie8, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3School of Medicine, Griffith University, Brisbane, Australia, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, 6AbbVie, Inc., Mettawa, IL, 7AbbVie, Inc., North Chicago, IL, 8Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2022

Keywords: Anti-TNF Drugs, clinical trial, Disease-Modifying Antirheumatic Drugs (Dmards), gender, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster III: PsA

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase 3 SELECT-PsA 1 trial (NCT03104400) evaluated responses to the Janus kinase inhibitor upadacitinib (UPA) vs the TNF inhibitor adalimumab (ADA) at Weeks (Wks) 24 and 56 in selected pt subgroups.

Methods: Pts in SELECT-PsA 1 were randomized 1:1:1:1 to UPA 15/30 mg once daily, ADA 40 mg every other wk, or placebo (PBO) followed by UPA 15/30 mg starting at Wk 24; treatment was double blinded until Wk 56.2 This subgroup analysis evaluated the efficacy of UPA 15 mg vs ADA based on pts’ ages (< 65 vs ≥65 years), sex (male [M] vs female [F]), BMI (< 30 vs ≥30 kg/m2), time since diagnosis (< 2 vs ≥2 years), and symptom duration (< 9 vs ≥9 years) at baseline (BL). Outcomes assessed included ≥20%/50%/70% improvement in ACR criteria (ACR20/50/70), ≥75%/90% improvement in Psoriasis Area and Severity Index (PASI75/90), and resolution of enthesitis, all at Wks 24 and 56; and change from BL in tender/swollen joint count in 68/66 joints (TJC68/SJC66), Physicians’ and Pts’ Global Assessment of disease activity (PhGA and PtGA), pts’ assessment of pain, high-sensitivity CRP (hsCRP), and Health Assessment Questionnaire Disability Index (HAQ-DI) through Wk 56.

Results: ACR20/50/70 response rates at Wk 24 were significantly greater with UPA vs PBO across all subgroups evaluated, but not across all subgroups with ADA vs PBO (Figure 1). For ACR20/50, treatment effect sizes differed by sex and BMI, with greater differences seen in M vs F and in pts with lower (< 30 kg/m2) vs higher BMI. ACR20/50/70 response rates at Wk 56 were either comparable or higher with UPA vs ADA in both sexes (Figure 2). Rates of resolution of enthesitis at Wk 56 were comparable between UPA vs ADA in both sexes, but tended to be higher in M vs F. Between-sex differences in Wk 56 PASI75/90 response rates were minimal with UPA, but notably higher rates were seen in M vs F treated with ADA, with significantly higher PASI75 response rates in F with UPA vs ADA. Changes from baseline in TJC68/SJC66 were generally comparable between sexes in both treatment groups (Figure 3). Mean hsCRP levels at BL were higher in M (UPA, 13.5; ADA, 12.4) vs F (UPA, 9.0; ADA, 9.3), and generally greater mean changes in hsCRP from BL to Wk 56 were observed for M vs F within treatment groups. Generally greater mean changes were also observed in HAQ-DI from BL to Wk 56 for M vs F within treatment groups. The same was true of PhGA and PtGA, albeit to a lesser extent. Pts’ assessment of pain at BL was lower for M (UPA, 5.8; ADA, 5.4) vs F (UPA, 6.5; ADA, 6.5). Significantly greater improvements from BL were seen at Wk 56 with UPA vs ADA in PhGA, PtGA, and HAQ-DI in F, and in PtGA, pts’ assessment of pain, and hsCRP in M.

Conclusion: We observed sex-based differences in response to UPA vs ADA in pts with PsA. Significantly greater improvements in ACR70, PtGA, pts’ assessment of pain, and hsCRP in M, and in ACR50/70, PASI75, PhGA, PtGA, and HAQ-DI in F, were seen with UPA vs ADA at Wk 56.

References
1. Coates LC, et al. Lancet Rheumatol 2022;4:E262–73.
2. McInnes IB, et al. N Engl J Med 2021;384:1227–39.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: L. Eder, AbbVie, Lilly, Novartis, UCB, Pfizer; L. Coates, AbbVie, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb (BMS), Eli Lilly, Gilead, Galapagos, Janssen, Medac, Novartis, Pfizer, UCB, Celgene, Biogen, Moonlake, GlaxoSmithKlein (GSK); P. Nash, AbbVie, BMS, Celgene, Gilead, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB; U. Kiltz, AbbVie, Amgen, Biogen, Fresenius, GSK, Hexal, Novartis, Pfizer, Biocad, Lilly, Grünenthal, Janssen, MSD, Roche, UCB; E. Lubrano, None; E. McDearmon-Blondell, AbbVie; T. Gao, AbbVie; A. Ogdie, AbbVie, Amgen, Novartis, Pfizer Inc, Bristol-Myers Squibb, Celgene, Janssen, CorEvitas, Gilead Sciences, Eli Lilly, GlaxoSmithKline, Happify Health, UCB.

To cite this abstract in AMA style:

Eder L, Coates L, Nash P, Kiltz U, Lubrano E, McDearmon-Blondell E, Gao T, Ogdie A. Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-patient-characteristics-including-sex-on-the-efficacy-of-upadacitinib-compared-with-adalimumab-in-patients-with-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-patient-characteristics-including-sex-on-the-efficacy-of-upadacitinib-compared-with-adalimumab-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology